We are live on ! Find out more
PMVP icon

PMV Pharmaceuticals
PMVP

115 hedge funds and large institutions have $470M invested in PMV Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 35 increasing their positions, 39 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

159% more call options, than puts

Call options by funds: $1.88M | Put options by funds: $727K

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

4% less funds holding

Funds holding: 120 → 115 (-5)

8.09% less ownership

Funds ownership: 127.52% → 119.42% (-8.1%)

10% less repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 39

19% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 16

24% less capital invested

Capital invested by funds: $614M → $470M (-$144M)

Holders
115
Holders Change
-5
Holders Change %
-4.17%
% of All Funds
1.85%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
13
Increased
35
Reduced
39
Closed
16
Calls
$1.88M
Puts
$727K
Net Calls
+$1.15M
Net Calls Change
+$961K

Top Buyers

Rank Fund Capital Flow
1
Verition Fund Management
Verition Fund Management
Connecticut
+$6.68M
2
Bank of America
Bank of America
North Carolina
+$5.76M
3
Citadel Advisors
Citadel Advisors
Florida
+$4.33M
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$1.79M
5
UBS Group
UBS Group
Switzerland
+$1.75M

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$20.4M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$8.23M
3
Vanguard Group
Vanguard Group
Pennsylvania
-$7.25M
4
JP Morgan Chase
JP Morgan Chase
New York
-$6.5M
5
State Street
State Street
Massachusetts
-$6.29M
Name Holding Trade Value Shares
Change 		Change in
Stake
PHS
26
PFM Health Sciences
California
$2.9M -$5.56M -521,448 -61%
BBA
27
Baker Bros. Advisors
New York
$2.8M – – –
Northern Trust
28
Northern Trust
Illinois
$2.79M +$44.9K +4,215 +1%
UBS Group
29
UBS Group
Switzerland
$2.47M +$1.75M +164,543 +137%
Rafferty Asset Management
30
Rafferty Asset Management
New York
$2.3M -$262K -24,546 -8%
MPAM
31
Monarch Partners Asset Management
Massachusetts
$2.29M +$566K +53,079 +25%
Voloridge Investment Management
32
Voloridge Investment Management
Florida
$2.2M +$195K +18,266 +8%
Charles Schwab
33
Charles Schwab
California
$2.19M +$37.1K +3,483 +1%
UBS AM
34
UBS AM
Illinois
$1.65M +$127K +11,901 +7%
SFM
35
Sphera Funds Management
Israel
$1.63M – – –
Barclays
36
Barclays
United Kingdom
$1.41M -$336K -31,552 -16%
HF
37
HRT Financial
New York
$1.35M +$951K +89,206 +135%
ACP
38
Acuta Capital Partners
California
$1.34M -$309 -29 -0%
EW
39
Evoke Wealth
California
$1.16M – – –
Qube Research & Technologies (QRT)
40
Qube Research & Technologies (QRT)
United Kingdom
$1.15M +$1.17M +109,387 +473%
Bank of New York Mellon
41
Bank of New York Mellon
New York
$1.07M +$3.69K +346 +0.3%
Citigroup
42
Citigroup
New York
$1.01M -$1.57M -146,864 -56%
Connor, Clark & Lunn Investment Management (CC&L)
43
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$1.01M +$1.23M +115,689 New
N
44
Nuveen
North Carolina
$859K -$189K -17,714 -15%
Ameriprise
45
Ameriprise
Minnesota
$699K -$53 -5 -0%
CSS
46
Cubist Systematic Strategies
Connecticut
$697K -$1.04M -97,949 -55%
Millennium Management
47
Millennium Management
New York
$640K -$927K -86,959 -54%
Jane Street
48
Jane Street
New York
$631K +$518K +48,593 +203%
PP
49
PDT Partners
New York
$577K +$506K +47,470 +252%
Marshall Wace
50
Marshall Wace
United Kingdom
$576K +$224K +21,000 +46%
1
2
3 4 5

PMVP Hedge Fund Activity: Q4 2022 in Review

115 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in PMV Pharmaceuticals (PMVP) for Q4 2022, worth a combined $470M — down 24% from $614M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of PMVP and 13 opened new positions — a net loss of 3 holders — while 39 trimmed existing stakes and 35 added.

The largest buyer was Verition Fund Management, adding an estimated $6.68M. The largest seller was RA Capital Management, exiting entirely with an estimated $20.4M sold.

  • 115 institutional investors held PMV Pharmaceuticals (PMVP) as of Q4 2022, down from 120 in Q3 2022.
  • Funds reported $470M of PMV Pharmaceuticals stock for Q4 2022, down 24% quarter-over-quarter.
  • 13 funds opened new PMV Pharmaceuticals positions in Q4 2022 and 16 closed out, a net change of -3 holders.
  • The largest PMV Pharmaceuticals buyer in Q4 2022 was Verition Fund Management, an estimated $6.68M added.
  • The largest PMV Pharmaceuticals seller in Q4 2022 was RA Capital Management, an estimated $20.4M sold.

Based on aggregated 13F filings for Q4 2022.